(Q36244265)

13 August 2017

Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer (English)

1 reference

13 August 2017

1 reference

Reiki Nishimura

1

1 reference

13 August 2017

Tomofumi Osako

2

1 reference

13 August 2017

Yasuhiro Okumura

3

1 reference

13 August 2017

Mitsuhiro Hayashi

4

1 reference

13 August 2017

Yasuo Toyozumi

5

1 reference

13 August 2017

Nobuyuki Arima

6

1 reference

13 August 2017

21 July 2010

1 reference

Experimental and Therapeutic Medicine

13 August 2017

1 reference

13 August 2017

1

1 reference

13 August 2017

5

1 reference

13 August 2017

747-754

1 reference

Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Ki67 in breast cancer: prognostic and predictive potential

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Proliferation marker Ki-67 in early breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3445951

The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer

22 September 2018

1 reference

12 December 2020

Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors

1 reference

12 December 2020

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

12 December 2020

Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

1 reference

12 December 2020

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

12 December 2020

Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer

1 reference

12 December 2020

p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study

1 reference

12 December 2020

Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

1 reference

12 December 2020

Identifiers

DOI

10.3892/ETM.2010.133

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

22993598

1 reference